Tacrolimus-induced Diabetic Ketoacidosis in a Polymyositis Patient Precipitated by Fluconazole: A Case Report and Review of the Literature

Hira Chaudhary¹, Shweta Kumar¹, Nagasudha L Chigurupati¹, Gregory A. Chang¹, Gul Bahtiyar¹, Madina Abduraimova¹ and Samy I. McFarlane^1,

¹Department of Medicine, SUNY-Downstate Health Sciences University, 450 Clarkson Avenue, Brooklyn, New York 11203, USA

Cite this paper

Hira Chaudhary, Shweta Kumar, Nagasudha L Chigurupati, Gregory A. Chang, Gul Bahtiyar, Madina Abduraimova and Samy I. McFarlane. Tacrolimus-induced Diabetic Ketoacidosis in a Polymyositis Patient Precipitated by Fluconazole: A Case Report and Review of the Literature. American Journal of Medical Case Reports. 2020; 8(3):76-78. doi: 10.12691/AJMCR-8-3-3

Abstract

Tacrolimus is a reversible calcineurin inhibitor. It is commonly used as an immunosuppressive drug in the treatment of T cell mediated diseases such as polymyositis, graft rejection in solid organ transplant, graft-versus-host disease in hematopoietic stem cell transplant, and is postulated to have diabetogenic potential. Fluconazole, on the other hand, is frequently prescribed antifungal therapy. Fluconazole increases the serum level of tacrolimus into the supratherapeutic range, thus developing drug toxicity if the dose is unadjusted. Diabetic ketoacidosis is a rare adverse drug effect reported with the use of tacrolimus. In this report, we present a case of DKA in a 60-year-old woman with polymyositis on low dose corticosteroids and tacrolimus, precipitated by the use of fluconazole. We highlight the pathophysiologic mechanisms underlying the effect of fluconazole on tacrolimus levels causing an accelerated development of DKA along with the review of literature on this potentially life-threatening condition.

Keywords

Tacrolimus, Fluconazole, Diabetic Ketoacidosis, Polymyositis

Copyright

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]	Peters DH, Fitton A, Plosker GL, Faulds D. Tacrolimus: a review of its pharmacology, and therapeutic potential in hepatic and renal transplantation drugs 1993; 46: 746-94.
[2]	Ammari Z, Pak SC, Ruzieh M, et al. Posttransplant Tacrolimus-Induced Diabetic Ketoacidosis: Review of the Literature. Case Rep Endocrinol. 2018; 2018: 4606491.
[3]	Redmon JB, Olson LK, Armstrong MB, Greene MJ, Robertson RP. Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. J Clin Invest. 1996; 98(12): 2786-93.
[4]	Odom A, Del Poeta M, Perfect J, Heitman J. The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein. Antimicrob Agents Chemother. 1997; 41(1): 156-161.
[5]	Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant. 2004; 4(4): 583-95.
[6]	David L. Paterson, & Nina Singh. (1997). Interactions between Tacrolimus and Antimicrobial Agents. Clinical Infectious Diseases, 25(6), 1430-1440.
[7]	Li Z, Sun F, Zhang Y, et al. Tacrolimus Induces Insulin Resistance and Increases the Glucose Absorption in the Jejunum: A Potential Mechanism of the Diabetogenic Effects. PLoS One. 2015; 10(11): e0143405.
[8]	Chen, Qing-Jie, et al. "Tacrolimus decreases insulin sensitivity without reducing fasting insulin concentration: a 2-year follow-up study in kidney transplant recipients." Renal failure. 37.4 (2015): 601-606.
[9]	Mañez R, Martin M, Raman D, et al. Fluconazole therapy in transplant recipients receiving FK506. Transplantation. 1994; 57(10): 1521-1523.